Trastuzumab Plus Gemcitabine-Cisplatin for Treatment-Naïve Human Epidermal Growth Factor Receptor 2–Positive Biliary Tract Adenocarcinoma: A Multicenter, Open-Label, Phase II Study (TAB) Patients were ...
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase ...
CNS metastases in EGFR-mutant NSCLC are prevalent and worsen prognosis, especially with acquired progression during treatment. Amivantamab plus lazertinib shows promising CNS activity, but current ...
PHILADELPHIA, June 29, 2021 /PRNewswire/ — Signant Health, the leader in evidence generation for modern clinical trials, today announced a new acceleration program that reduces study setup timelines ...
Clinical research and health tech companies Medidata and Cogstate are joining forces to speed up trials and improve outcomes measurement across diseases of the central nervous system, the partners ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results